CN117024595A - Monoclonal antibody against human ST2 and use thereof - Google Patents
Monoclonal antibody against human ST2 and use thereof Download PDFInfo
- Publication number
- CN117024595A CN117024595A CN202311288125.4A CN202311288125A CN117024595A CN 117024595 A CN117024595 A CN 117024595A CN 202311288125 A CN202311288125 A CN 202311288125A CN 117024595 A CN117024595 A CN 117024595A
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000852968 Homo sapiens Interleukin-1 receptor-like 1 Proteins 0.000 title claims abstract description 50
- 102000055002 human IL1RL1 Human genes 0.000 title claims abstract description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 47
- 238000001514 detection method Methods 0.000 claims abstract description 30
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 11
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 10
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 10
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims description 10
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 10
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims description 10
- 238000002965 ELISA Methods 0.000 claims description 7
- 238000003317 immunochromatography Methods 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 239000000427 antigen Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010003445 Ascites Diseases 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000003118 sandwich ELISA Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 101100112111 Caenorhabditis elegans cand-1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 101710122194 Gene 2 protein Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101710137426 Replication-associated protein G2P Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001054 cardiac fibroblast Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2470/00—Immunochemical assays or immunoassays characterised by the reaction format or reaction type
- G01N2470/04—Sandwich assay format
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention belongs to the technical field of biology, and relates to an anti-human ST2 monoclonal antibody and application thereof, wherein the anti-human ST2 monoclonal antibody comprises a capture antibody and a detection antibody, the capture antibody comprises an amino acid sequence shown as SEQ ID NO. 1 and an amino acid sequence shown as SEQ ID NO. 2, and the detection antibody comprises an amino acid sequence shown as SEQ ID NO. 17 and an amino acid sequence shown as SEQ ID NO. 18. The invention discloses a monoclonal antibody with high affinity and specificity against human ST2, in particular a monoclonal antibody which can form a double-antibody sandwich detection function.
Description
Technical Field
The invention relates to the technical field of biological medicine, in particular to an anti-human ST2 monoclonal antibody and application thereof.
Background
Human soluble growth stimulatory expressed gene 2 protein (Growth Stimulation Expressed Gene, st 2), one of the members of the IL-1 (interleukin 1) receptor family. St2 is found to be expressed by cardiac fibroblasts and cardiomyocytes, a cardiomyopathy protein induced by biomechanical stress, and its gene is expressed in mast cells, activated helper T cells 2 (Th 2), macrophages and cardiomyocytes. sST2 (soluble ST 2) in human blood can competitively bind to IL-33, so that cardiac muscle is affected, cardiac structure and function are affected, and the disease development rate is increased. Therefore, when heart failure occurs, the level of sST2 is significantly increased, and thus the damage effect on the heart is increased, and sST2 plays an important role in diagnosis, treatment and risk prediction of heart failure patients as a new generation heart failure marker.
The immunoassay technology based on antigen-antibody specific recognition and combination plays an important role in the field of accurate and rapid detection of ST2, such as common ELISA, fluorescent immunochromatography test paper, latex immune turbidimetry and other methods. Antibody species used in the immunoassay field include polyclonal antibodies, monoclonal antibodies, antibody fragments prepared based on genetic engineering techniques, single domain heavy chain antibodies, and the like. Among them, monoclonal antibodies are highly homogeneous antibodies raised against only a specific epitope by a single B cell clone. Monoclonal antibodies are typically prepared by hybridoma cell technology, e.g., by fusing murine myeloma cells with antigen-immunized, germ-line mouse B cells, known as hybridoma cells, which have the characteristics of unlimited in vitro propagation and synthesis and secretion of specific antibodies.
How to obtain the monoclonal antibody of high affinity and specificity anti-human ST2, in particular to a monoclonal antibody which can form a double-antibody sandwich detection function, has a crucial effect on the high-sensitivity and accurate detection of ST2, and is also a key point for limiting the performance of an immunoassay method of ST 2.
Disclosure of Invention
The invention provides an anti-human ST2 monoclonal antibody and application thereof, so as to obtain a high-affinity and specific anti-human ST2 monoclonal antibody, in particular to a monoclonal antibody with a double-antibody sandwich detection function.
In one aspect, the invention provides a monoclonal antibody against human ST2, comprising a capture antibody (abbreviated as C11 in the present invention) and a detection antibody (abbreviated as D12 in the present invention);
the capture antibody comprises the amino acid sequence: EVLLQQSGPELVKPGASVKIPCKASGYTFTDYNMDWVKQSHGKNLEWIGDIDPNNGGTIYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSGVYYCARFDAYFSYWYFDVWGAGTTVTVSS (SEQ ID NO. 1) and amino acid sequence: DIVLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIRELNTFGGGTKLEIK (SEQ ID NO. 2);
the detection antibody comprises an amino acid sequence: QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDDVKQYNPALKSRLTISKDTSSSQVFLKIASVDTADIATYYCARLGGNWDYFDYWGQGTTLTVSS (SEQ ID NO. 15) and DIVLTQSPASLVVSLGQRATISCRASESVDSCGVSFMKWLQQKPGQPPKLLIYVASKVESGVPARFGGSGSGTDFSLNIHPVEEDDFAVYFCQQSRKVPWTFGGGTKLEIK (SEQ ID NO. 16).
The monoclonal antibody against human ST2, wherein the nucleotide sequence of the amino acid sequence shown as SEQ ID NO. 1 is: gaggtcctgctgcaacagtctggacctgagctggtgaagcctggggcttcagtgaagataccctgcaaggcttctggatacacattcactgactacaacatggactgggtgaagcagagtcatggaaagaaccttgagtggattggagatattgatcctaacaatggtggtactatctacaatcagaagttcaagggcaaggccacattgactgttgacaagtcctccagcacagcctacatggagctccgcagcctgacatctgaggactctggagtctattactgtgcaagatttgatgcttactttagctactggtacttcgatgtctggggcgcagggaccacggtcaccgtctcctca (SEQ ID NO. 3);
the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO. 2 is: gacattgtgctgacacagtctcctgcttccttagctgtatctctggggcagagggccaccatctcatacagggccagcaaaagtgtcagtacatctggctatagttatatgcactggaaccaacagaaaccaggacagccacccagactcctcatctatcttgtatccaacctagaatctggggtccctgccaggttcagtggcagtgggtctgggacagacttcaccctcaacatccatcctgtggaggaggaggatgctgcaacctattactgtcagcacattagggagcttaacacgttcggaggggggaccaagctggaaataaaa (SEQ ID NO. 4);
the nucleotide sequence encoding the amino acid sequence shown as SEQ ID NO. 15 is: caggttactctgaaagagtctggccctgggatattgcagccctcccagaccctcagtctgacttgttctttctctgggttttcactgagcacttctggtatgggtgtaggctggattcgtcagccatcagggaagggtctggagtggctggcacacatttggtgggatgatgtcaagcagtataacccagccctgaagagccgactgactatctccaaggatacctccagcagccaggtattcctcaagatcgccagtgtggacactgcagatattgccacatactactgtgctcgattaggcgggaactgggactactttgactactggggccaaggcaccactctcacagtctcctca (SEQ ID NO. 17);
the nucleotide sequence encoding the amino acid sequence shown as SEQ ID NO. 16 is: gacattgtgctcacccaatctccggcttctttggttgtgtctctagggcagagggccaccatctcctgcagagccagcgaaagtgttgacagttgtggcgttagttttatgaagtggctccaacagaaaccaggacagccacccaaactcctcatctatgttgcatccaaagtagaatctggggtccctgccaggtttggtggcagtgggtctgggacagacttcagcctcaacatacatcctgtggaggaggatgattttgcagtttatttctgtcagcaaagtaggaaggttccttggacgttcggtggaggcaccaagctggaaatcaaa (SEQ ID NO. 18).
The monoclonal antibody against human ST2, wherein the amino acid sequences CDR1, CDR2 and CDR3 of the complementarity determining regions of the heavy chain of the capture antibody are respectively:
CDR1：GYTFTDYN（SEQ ID NO .5）；
CDR2：IDPNNGGT（SEQ ID NO .6）；
CDR3：ARFDAYFSYWYFDV（SEQ ID NO .7）。
the amino acid sequence CDR1 of the complementarity determining region of the light chain of the capture antibody is: KSVSTSGYSY (SEQ ID NO. 8), the amino acid sequence CDR2 of the complementarity determining region of the light chain of the capture antibody being: LVS, the amino acid sequence CDR3 of the complementarity determining region of the light chain of the capture antibody is: QHIRELNT (SEQ ID NO. 9).
The amino acid sequences CDR1, CDR2 and CDR3 of the complementarity determining regions of the heavy chain of the detection antibody are respectively:
CDR1：GFSLSTSGMG（SEQ ID NO .19）；
CDR2：IWWDDVK（SEQ ID NO .20）；
CDR3：ARLGGNWDYFDY（SEQ ID NO .21）；
the amino acid sequence CDR1 of the complementarity determining region of the light chain of the detection antibody is: ESVDSCGVSF (SEQ ID NO. 22), the amino acid sequence CDR2 of the complementarity determining region of the light chain of said detection antibody being: VAS, the amino acid sequence CDR3 of the complementarity determining region of the light chain of the detection antibody is: QQSRKVPWT (SEQ ID NO. 23).
The monoclonal antibody against human ST2, wherein the nucleotide sequence of the amino acid sequence shown as SEQ ID NO. 5 is: ggatacacattcactgactacaac (SEQ ID NO. 10);
the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO. 6 is: attgatcctaacaatggtggtact (SEQ ID NO. 11);
the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO. 7 is: gcaagatttgatgcttactttagctactggtacttcgatgtc (SEQ ID NO. 12).
The nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO. 8 is: aaaagtgtcagtacatctggctatagttat (SEQ ID NO. 13);
the nucleotide sequence encoding amino acid sequence LVS is cttgtatcc;
the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO. 9 is: cagcacattagggagcttaacacg (SEQ ID NO. 14);
the nucleotide sequence encoding the amino acid sequence shown as SEQ ID NO. 19 is: gggttttcactgagcacttctggtatgggt (SEQ ID NO. 24);
the nucleotide sequence encoding the amino acid sequence shown as SEQ ID NO. 20 is: atttggtgggatgatgtcaag (SEQ ID NO. 25);
the nucleotide sequence encoding the amino acid sequence shown as SEQ ID NO. 21 is: gctcgattaggcgggaactgggactactttgactac (SEQ ID NO. 26);
the nucleotide sequence encoding the amino acid sequence shown as SEQ ID NO. 22 is: gaaagtgttgacagttgtggcgttagtttt (SEQ ID NO. 27)
The nucleotide sequence encoding the amino acid sequence VAS is gttgcatcc;
the nucleotide sequence encoding the amino acid sequence shown as SEQ ID NO. 23 is: cagcaaagtaggaaggttccttggacg (SEQ ID NO. 28).
In another aspect, the invention provides an application of the monoclonal antibody against human ST2, wherein the monoclonal antibody against human ST2 is used for detecting the ST2 content in a sample in a pairing mode by adopting a double-antibody sandwich method.
The application of the monoclonal antibody against the human ST2, wherein the method of the double antibody sandwich comprises an enzyme-linked immunoassay method and an immunochromatography method.
The beneficial effects are that:
the monoclonal antibody against human ST2 provided by the invention comprises a capture antibody and a detection antibody, and experimental results show that both the capture antibody and the detection antibody have high affinity and specificity detection activity on human ST2 antigen, and the monoclonal antibody against human ST2 can be used for immunological analysis of ST2 in a double-antibody sandwich mode, and has important significance for high-sensitivity and accurate detection of ST2, including ELISA detection, immunochromatography and other immunological analysis detection types based on antigen-antibody specific reaction.
Drawings
FIG. 1 is a schematic diagram showing the results of double antibody sandwich ELISA detection of ST2 antigen and other proteins.
Detailed Description
In order that the invention may be readily understood, a more complete description of the invention will be rendered by reference to the appended drawings. Several embodiments of the invention are presented in the figures. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
EXAMPLE 1 preparation of human ST2 monoclonal antibodies
1) Animal immunization:
human ST2 antigen is taken as immunogen, the immunogen is mixed with Freund's adjuvant in equal volume, vortex oscillation is carried out until the immunogen is completely emulsified, and the immunization is carried out by adopting a BaLB/C mouse abdominal and back subcutaneous multipoint injection mode. Primary immunization was performed with freund's complete adjuvant at an immunogen dose of 100 μg/dose; the immunization was then followed with Freund's incomplete adjuvant and the immunogen dose was successively reduced, 1 immunization every 4 weeks, for a total of 3 immunizations. Two weeks after the third immunization, tail blood of the mice is taken, the serum antibody titer in the tail blood is measured by an indirect ELISA method, and the mice with the highest titers are directly boosted by using immunogen three days before fusion, wherein the immune dose is 40 micrograms/mouse.
2) Preparation and screening of hybridoma cells
Selected immunized mice were sacrificed by pulling the neck, spleens were removed from the ultra clean bench and ground, mouse myeloma cells SP2/0 were mixed with spleen cells in a ratio of 1:10, 50% PEG pre-warmed in advance was added for cell fusion, and the mixture was added dropwise to a 96-well cell culture plate with feeder cells. Observing the cell state through a microscope after fusion, performing semi-quantitative liquid exchange on the 5 th day after fusion, and continuously culturing until the seventh day, and then exchanging the whole liquid.
Cell fusion is carried out for about 7-10 days, cell supernatant in a cell culture plate is sucked, the secretion of antibodies in the cell supernatant is measured by adopting an indirect ELISA method, positive cell plate holes are screened, and subcloning is carried out by adopting a limiting dilution method. The ST2 protein is coated, a blank control hole is PBS, a negative control is a culture medium, and a positive control is serum of eyeball blood of a immunized mouse. When the positive rate of the selected monoclonal cells in the 96-hole cell culture plate reaches 100%, the selected monoclonal cells are judged to be positive monoclonal, and the selected monoclonal cells are frozen and expanded in time.
3) Preparation and purification of monoclonal antibody ascites
Taking about 8-week-old Balb/c mice, injecting liquid paraffin one week in advance for pre-stimulation, and promoting secretion and aggregation of nutrient substances in abdominal cavities of the mice. The hybridoma cell lines obtained were expanded to the desired number, centrifuged, carefully washed, resuspended in sterile 75% physiological saline and injected into the abdomen of mice by intraperitoneal injection. And collecting ascites after the abdomen of the mice is obviously enlarged for about one week, centrifuging for 10min at 10000r/min, and collecting supernatant to obtain monoclonal antibody ascites.
And purifying the collected ascites by using a Protein G affinity chromatography purification column. Before loading, ascites is filtered by a microporous membrane to be used as a loading liquid, and a binding buffer solution (0.15M NaCl,20mM Na) 2 HPO 4 pH 7.4), loading the filtered ascites to a chromatographic column, eluting with an elution buffer (0.1M citric acid, pH 2.5-3.0) after equilibration, and collecting the eluate rich in antibodies. The eluate is acidic, and the pH should be immediately adjusted to neutral using a neutralization buffer (1M Tris-HCl, pH 9.0) to prevent antibody inactivation, followed by identification by SDS-PAGE electrophoresis to obtain the capture antibody C11 and the detection antibody D12.
4) Determination of heavy and light chain variable regions of monoclonal antibody secreted by hybridoma cells
Will be able to stably secrete sST2 monocHybridoma cell strain of the diabody is cultured to 1×10 6 cell/mL, discard supernatant, add 1mL Trizol reagent, gently shake, add 200. Mu.L chloroform, shake upside down for 30s, place on ice for 10min; centrifuging at 4deg.C for 15min at 12000g, transferring the supernatant to a new enzyme-free centrifuge tube, adding isopropanol of equal volume, and standing on ice for 10min; centrifuging at 4 ℃ for 10min with 12000g, discarding supernatant, adding 1mL of 75% ethanol, centrifuging at 4 ℃ for 5min with 7500g, drying in a super clean bench under low-speed ventilation for 5min, adding 30-50 mu L of enzyme-free sterile water, and mixing well to dissolve RNA. Reverse transcription was performed using 1. Mu.g total RNA as template and following the instructions of Hifair III 1st Strand cDNA Synthesis Kit kit. Designing upstream and downstream primers of a heavy chain variable region of the monoclonal antibody respectively, and amplifying cDNA obtained by reverse transcription, wherein the reaction parameters are as follows: 94℃for 5min,94℃for 10s,60℃for 20s,72℃for 30s, 25 cycles, and then 72℃for 5min. The obtained amplification product was identified by 1% agarose gel, and the sequence of the obtained product was determined.
5) Affinity constant determination
The affinity constant of the obtained anti-human ST2 monoclonal antibody is determined by adopting a biological film interference technology, and the specific orientation is as follows: fixing human ST2 recombinant protein with His histidine tag protein by adopting a capture HIS chip, then respectively adding C11 and D12 monoclonal antibodies with different concentrations diluted by PBS, analyzing interaction force between organisms, and displaying K of C11 and D12 by detection results D The values are 0.5X10 respectively -10 M and 0.2X10 g -10 M, all showed higher affinity.
EXAMPLE 2 double antibody sandwich ELISA assay for ST2 antigen
Respectively labeling monoclonal antibodies C11 and D12 by HRP enzyme, pairing the C11 monoclonal antibody and the D12 monoclonal antibody, and detecting ST2 antigen by double-antibody sandwich ELISA, wherein the specific method comprises the following steps: coating an anti-human ST2 antibody C11 (or D12) on an ELISA plate, and incubating overnight at 4 ℃; the following day, after 3 washes with PBST (10 mM PBS, 0.05% Tween-20 (v/v)), blocking with PBS containing 3% skimmed milk powder, and incubation at 37deg.C for 1 hr; adding 100 μl of human ST2 antigen or other proteins, incubating at 37deg.C for 0.5 hr, washing the plate, adding HRP enzyme labeled anti-human ST2 antibody D12 (or C11), incubating at 37deg.CAnd 1 hour. Then color development with TMB substrate, reading OD value, specifically OD 450 。
Referring to fig. 1, the above experimental results show that: as the concentration of the input ST2 antigen increases, the OD value of the plate hole of the monoclonal antibody shows gradient rise, while the plate hole added with non-ST 2 antigen protein does not have binding, which indicates that the obtained monoclonal antibody has excellent binding performance and specificity on ST2 antigen.
Example 3 application of monoclonal antibody in detection of ST2 antigen by immunochromatography test strip
1) Antibody labelling
The specific method comprises the steps of taking 5 mu L of 10mg/mL carboxylated fluorescent microspheres into a 2mL centrifuge tube containing 1mL of 10 mM PB (pH 6.0, containing 0.005% SDS), adding 1 mu L of 10mg/mL EDC and 2 mu L of NHSS solutions which are freshly prepared respectively, quickly mixing, and activating for 30 min at room temperature by using a vertical mixer. After the activation, centrifuging at 12000rpm for 12min, removing the supernatant, supplementing to 0.5mL with PB (pH 8.0), performing ultrasound for 10min to fully disperse, adding 25 μg of ST2 monoclonal antibody (D12), mixing well, coupling for 2h at room temperature by a rotary mixer, adding 150 μl of 2% sodium caseinate, sealing for 1h, centrifuging at 12000rpm for 12min, removing the supernatant, supplementing to 500 μl with a complex solution, and reserving at 4 ℃.
2) Preparation of immunochromatography test strip
The labeled antibody probes were mixed with a multiplex solution (5% trehalose, 1% BSA,0.5% Tween-20,0.2% Casein Na, 20mM Tris,0.02%NaN3,pH 8.5) 1:4, diluting, spraying 40 mu L/cm on the treated bonding pad, drying by blowing at 37 ℃ for 1h, assembling and cutting with NC film CN95 (ST 2 monoclonal antibody C11 with T line of 2mg/mL and goat anti-mouse secondary antibody with C line of 2 mg/mL) and sample pad to prepare the immunochromatographic test paper.
3) Detection of ST2 antigen
ST2 antigens with different concentrations are prepared by using sample loading buffer solution, the ST2 antigens are added into loading holes of test strips one by one in a dropwise manner, after the test strips are subjected to stationary chromatography for 15 minutes, fluorescent values on C, T lines are read by using a fluorescent immunochromatography test paper detector, and the results are shown in Table 1.
TABLE 1
It can be seen from Table 1 that the anti-human ST2 monoclonal antibodies of the present invention can achieve high sensitivity and wide linear range detection of ST2 antigen.
The foregoing examples illustrate only a few embodiments of the invention and are described in detail herein without thereby limiting the scope of the invention. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the invention, which are all within the scope of the invention. Accordingly, the scope of protection of the present invention is to be determined by the appended claims.
Claims (4)
1. A monoclonal antibody against human ST2, comprising a capture antibody and a detection antibody, wherein the amino acid sequences CDR1, CDR2 and CDR3 of the complementarity determining regions of the heavy chain of the capture antibody are shown in SEQ ID No. 5, SEQ ID No. 6 and SEQ ID No. 7, respectively, the amino acid sequence CDR1 of the complementarity determining regions of the light chain of the capture antibody is shown in SEQ ID No. 8, and the amino acid sequence CDR2 of the complementarity determining regions of the light chain of the capture antibody is: LVS, the amino acid sequence CDR3 of the complementarity determining region of the light chain of the capture antibody is shown as SEQ ID NO. 9;
the amino acid sequences CDR1, CDR2 and CDR3 of the complementarity determining regions of the heavy chain of the detection antibody are respectively shown in SEQ ID NO. 19, SEQ ID NO. 20 and SEQ ID NO. 21, the amino acid sequence CDR1 of the complementarity determining region of the light chain of the detection antibody is shown in SEQ ID NO. 22, and the amino acid sequence CDR2 of the complementarity determining region of the light chain of the detection antibody is as follows: VAS, the amino acid sequence CDR3 of the complementarity determining region of the light chain of the detection antibody is shown as SEQ ID NO. 23.
2. The monoclonal antibody against human ST2 according to claim 1, wherein the nucleotide sequences encoding the amino acid sequences shown as SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7 are shown as SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, the nucleotide sequence encoding the amino acid sequence shown as SEQ ID No. 8 is shown as SEQ ID No. 13, the nucleotide sequence encoding the amino acid sequence LVS is cttgtatcc, the nucleotide sequence encoding the amino acid sequence shown as SEQ ID No. 9 is shown as SEQ ID No. 14;
the nucleotide sequences of the amino acid sequences shown as SEQ ID NO. 19, SEQ ID NO. 20 and SEQ ID NO. 21 are shown as SEQ ID NO. 24, SEQ ID NO. 25 and SEQ ID NO. 26 respectively;
the nucleotide sequence of the amino acid sequence shown as SEQ ID NO. 22 is shown as SEQ ID NO. 27, the nucleotide sequence of the amino acid sequence VAS is shown as gttgcatcc, and the nucleotide sequence of the amino acid sequence shown as SEQ ID NO. 23 is shown as SEQ ID NO. 28.
3. Use of the monoclonal antibody against human ST2 according to claim 1, wherein the monoclonal antibody against human ST2 is used in a paired manner to detect ST2 content in a sample by means of a double antibody sandwich method.
4. The use of a monoclonal antibody against human ST2 according to claim 3, wherein the method of double antibody sandwich comprises enzyme-linked immunoassay, immunochromatography.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311288125.4A CN117024595B (en) | 2023-10-08 | 2023-10-08 | Monoclonal antibody against human ST2 and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311288125.4A CN117024595B (en) | 2023-10-08 | 2023-10-08 | Monoclonal antibody against human ST2 and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117024595A true CN117024595A (en) | 2023-11-10 |
| CN117024595B CN117024595B (en) | 2024-01-26 |
Family
ID=88645171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311288125.4A Active CN117024595B (en) | 2023-10-08 | 2023-10-08 | Monoclonal antibody against human ST2 and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117024595B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030124624A1 (en) * | 2000-03-21 | 2003-07-03 | Medical Biological Laboratories Co., Ltd. | Monoclonal antibody and method and kit for immunoassay of soluble human ST2 |
| CN104151416A (en) * | 2013-05-15 | 2014-11-19 | 中国科学院上海巴斯德研究所 | Anti-human sST2 monoclonal antibody and application thereof |
| CN111308086A (en) * | 2020-02-21 | 2020-06-19 | 苏州旭光科星抗体生物科技有限公司 | Enzyme-linked immunoassay kit for detecting soluble ST2 content and application thereof |
| CN112480254A (en) * | 2019-09-12 | 2021-03-12 | 上海麦济生物技术有限公司 | Antibody for resisting human interleukin-33 receptor and preparation method and application thereof |
| CN113214395A (en) * | 2020-01-21 | 2021-08-06 | 迈威(上海)生物科技股份有限公司 | anti-ST 2 antibodies and uses thereof |
| WO2022239820A1 (en) * | 2021-05-13 | 2022-11-17 | 公益財団法人神戸医療産業都市推進機構 | Anti-human pd-1 agonist antibody for treating or preventing inflammatory diseases, and pharmaceutical composition containing same |
| CN116199783A (en) * | 2022-12-22 | 2023-06-02 | 山东纳睿博恩生物医药科技有限公司 | ALP monoclonal antibody and application thereof |
| CN116396384A (en) * | 2023-01-17 | 2023-07-07 | 武汉爱博泰克生物科技有限公司 | Rabbit monoclonal antibody aiming at mouse adiponectin, application of rabbit monoclonal antibody and double-antibody sandwich method ELISA (enzyme-linked immunosorbent assay) kit |
| US20230272086A1 (en) * | 2020-05-12 | 2023-08-31 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | St2 antigen binding protein |
-
2023
- 2023-10-08 CN CN202311288125.4A patent/CN117024595B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030124624A1 (en) * | 2000-03-21 | 2003-07-03 | Medical Biological Laboratories Co., Ltd. | Monoclonal antibody and method and kit for immunoassay of soluble human ST2 |
| CN104151416A (en) * | 2013-05-15 | 2014-11-19 | 中国科学院上海巴斯德研究所 | Anti-human sST2 monoclonal antibody and application thereof |
| CN112480254A (en) * | 2019-09-12 | 2021-03-12 | 上海麦济生物技术有限公司 | Antibody for resisting human interleukin-33 receptor and preparation method and application thereof |
| CN113214395A (en) * | 2020-01-21 | 2021-08-06 | 迈威(上海)生物科技股份有限公司 | anti-ST 2 antibodies and uses thereof |
| US20230220086A1 (en) * | 2020-01-21 | 2023-07-13 | Mabwell (shanghai) Bioscience Co., Ltd. | Anti-st2 antibody and application thereof |
| CN111308086A (en) * | 2020-02-21 | 2020-06-19 | 苏州旭光科星抗体生物科技有限公司 | Enzyme-linked immunoassay kit for detecting soluble ST2 content and application thereof |
| US20230272086A1 (en) * | 2020-05-12 | 2023-08-31 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | St2 antigen binding protein |
| WO2022239820A1 (en) * | 2021-05-13 | 2022-11-17 | 公益財団法人神戸医療産業都市推進機構 | Anti-human pd-1 agonist antibody for treating or preventing inflammatory diseases, and pharmaceutical composition containing same |
| CN116199783A (en) * | 2022-12-22 | 2023-06-02 | 山东纳睿博恩生物医药科技有限公司 | ALP monoclonal antibody and application thereof |
| CN116396384A (en) * | 2023-01-17 | 2023-07-07 | 武汉爱博泰克生物科技有限公司 | Rabbit monoclonal antibody aiming at mouse adiponectin, application of rabbit monoclonal antibody and double-antibody sandwich method ELISA (enzyme-linked immunosorbent assay) kit |
Non-Patent Citations (3)
| Title |
|---|
| CHIH-CHENG CHUANG ET AL.: "Anti-ST2 monoclonal antibody inhibits eosinophil infiltration in Angiostrongylus cantonensis-infected mice", 《JOURNAL OF MICROBIOLOGY, IMMUNOLOGY AND INFECTION》, vol. 49, pages 91 - 96 * |
| KURAOKA, M. ET AL.: "immunoglobulin heavy chain variable region, partial [Mus musculus], GenBank:UNP37070.1", 《GENPEPT》, pages 1 - 2 * |
| 汪慧: "人可溶性生长刺激表达基因2蛋白的真核表达及多克隆抗体的制备", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》, no. 2, pages 059 - 161 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117024595B (en) | 2024-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108084255A (en) | A kind of preparation of canine recombinant c reactive protein and its monoclonal antibody | |
| CN117820483B (en) | Cat N-terminal brain natriuretic peptide precursor protein monoclonal antibody, detection test strip and application | |
| CN102232087A (en) | Antibodies to modified human IGF-1/E peptides | |
| CN102124100A (en) | A monoclonal antibody specifically binding to VEGF and the hybridoma secreting same and uses thereof | |
| CN116836270B (en) | Monoclonal antibody of anti-bluetongue virus VP7 protein, preparation method and application | |
| US10634676B2 (en) | Method and kit for simultaneously detecting human parvovirus B19 antigen and antibody | |
| CN117024595B (en) | Monoclonal antibody against human ST2 and use thereof | |
| WO2017107131A1 (en) | Tp recombinant antigen, and preparation method and application thereof | |
| CN114349852B (en) | anti-H3N 2 influenza virus hemagglutinin protein monoclonal antibody ZJU32-01 and application thereof in detection | |
| JPS63123395A (en) | Anti-pci monoclonal antibody | |
| EP3239711A2 (en) | Method for measuring anti-drug antibody | |
| CN114134123A (en) | Monoclonal antibody of pregnancy-associated glycoprotein and application of monoclonal antibody in early pregnancy detection of cattle | |
| JPH0572207A (en) | Immunoassay method using non-crossing reactive ceagene-family-member antibody | |
| KR20210116115A (en) | Antibody binding to Porcine Epidemic Diarrhea virus and use thereof | |
| CN109652382A (en) | A kind of application of Procalcitonin monoclonal antibody hybridoma cell strain and its monoclonal antibody | |
| CN114456265B (en) | anti-HFABP monoclonal antibody and application thereof | |
| CN117088977B (en) | Canine C reactive protein monoclonal antibody, detection test strip and application | |
| CN113512119B (en) | anti-CA 125 nano antibody 5D2 and application thereof | |
| CN116769023B (en) | Mouse anti-marneffei basket mannoprotein hybridoma cell strain, monoclonal antibody and application | |
| CN115057935A (en) | Anti-human elastase inhibitory protein antibody, kit, preparation method and application thereof | |
| CN114957456B (en) | Monoclonal antibody ZJU-A1A3 of influenza A virus hemagglutinin protein and application thereof in detection | |
| CN110054675B (en) | Immunogenic polypeptide, anti-TTC 36 antibody CP4-3 and application | |
| CN102549014A (en) | Human serum amyloid-A3 antibody and use thereof | |
| JP4028925B2 (en) | Monoclonal antibody | |
| CN104830804B (en) | The monoclonal antibody hybridoma and its monoclonal antibody of a kind of Clonorchiasis Sinensis and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |